Wells Fargo raised the firm’s price target on Glaukos (GKOS) to $160 from $153 and keeps an Overweight rating on the shares. The firm notes Glaukos reported Q4 sales above consensus, driven by iDose and OUS MIGS, offsetting weaker core U.S. MIGS due to LCD headwinds. 2025 sales guidance brackets the Street, with iDose sales expected to be over $100M. Wells sees good momentum for Glaukos into 2025.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos: Surpassing Milestones with Robust Growth in Glaucoma Segment and Promising iDose Integration
- Glaukos Corporation Reports Strong 2024 Financial Results
- Closing Bell Movers: Booking gains 3%, Akamai down 8% on earnings
- Glaukos down 14% at $135 after Q4 results and guidance
- Glaukos Reports Record Sales and Positive Revenue Outlook